Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

J. Hickson, LaTonya; Prata, Larissa; A. Bobart, Shane; K. Evans, Tamara; Giorgadze, Nino; Hashmi, Shahrukh; M. Herrmann, Sandra; D. Jensen, Michael; Jia, Qingyi; L. Jordan, Kyra; A. Kellogg, Todd; Khosla, Sundeep; M. Koerber, Daniel; B. Lagnado, Anthony; K. Lawson, Donna; K. LeBrasseur, Nathan; O. Lerman, Lilach; M. McDonald, Kathleen; J. McKenzie, Travis; F. Passos, João; J. Pignolo, Robert; Pirtskhalava, Tamar; M. Saadiq, Ishran; K. Schaefer, Kalli; C. Textor, Stephen; Victorelli, Stella; L. Volkman, Tammie; Xue, Ailing; Wentworth, Mark; O. Wissler Gerdes, Erin; Zhu, Yi; Tchkonia, Tamar; L. Kirkland, James

doi:10.1016/j.ebiom.2019.08.069

Public

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Published in EBioMedicine • Sep 1, 2019

Authors:

LaTonya J. Hickson

Larissa Prata

Shane A. Bobart

Abstract

BACKGROUND: Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q)...

Subject

Adipose tissue

Medicine

Senescence

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!